Loading
A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT04176848 by Canadian Cancer Trials Group, with 15 participants planned, started 2020-08-10. Conditions recorded: Breast Cancer. Interventions recorded: CFI-400945 and Durvalumab.
Shares CFI-400945, Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares CFI-400945, Treadwell Therapeutics and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics, Breast cancer (all types) and the tag pipeline.
Shares CFI-400945, Breast cancer (all types) and the tag pipeline.
Shares Treadwell Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/